Onco Wiki / Biomarcador

IGHV (inmunoglobulina región variable de cadena pesada) estado mutacional

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDBIO-IGHV-MUTATIONAL-STATUS
TipoBiomarcador
Aliaces
IGHVIGHV (мутаційний статус варіабельного регіону важкого ланцюга імуноглобуліну)Estado de la mutación IGHVEstado de mutación IGHVMutado por GHIVIGHV-unmutated
Situaciónreviewed 2026-04-25 | pending_clinical_signoff
EnfermedadesDIS-CLL
FuentesSRC-NCCN-BCELL-2025

Datos sobre biomarcadores

Tipo de biomarcadorgene_mutation
Detalles de la mutación{"functional_impact": "marker of post-germinal-center maturation", "gene": "IGHV (heavy chain variable region — multiple V genes)", "variant_type": "somatic hypermutation status"}
Medición
MétodoPCR + secuenciación de Sanger del gen clonal IGHV; calcular % homología de gérmenes
Unidadescategorical (mutated <98% germline | unmutated ≥98% germline)
Productos químicos y químicosBIO-CLL-HIGH-RISK-GENETICS

Notas

Cross-disease relevance: - **CLL/SLL** (primary use): unmutated IGHV (≥98% germline homology) = adverse; mutated = favorable. Historically drove FCR (mutated did well long-term) vs BR (unmutated similar). Modern era: BTKi/VenO work regardless of IGHV status, BUT IGHV-unmutated is one component of the CLL high-risk composite (along with TP53/del 17p/complex karyotype) that drives toward fixed-duration VenO over BTKi continuous in some guidelines. - **MCL** (subset): mutated IGHV in nodal subset (germinal-center-like) behaves more indolently; unmutated in mantle-zone subset more aggressive. Not algorithm-driving currently. - **WM**: IGHV usage informs B-cell ontogeny but not treatment choice. Direct algorithm impact in our KB: triggers RF-CLL-HIGH-RISK when unmutated alone or part of composite. Standalone trigger now wired via this entity.

Utilizado por

Relevancia terapéutica

Biomarcador

Señal de alerta